AZURRX BIOPHARM (AZRX)
(Delayed Data from NSDQ)
$2.55 USD
+0.05 (2.11%)
Updated May 3, 2019 03:59 PM ET
After-Market: $2.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.55 USD
+0.05 (2.11%)
Updated May 3, 2019 03:59 PM ET
After-Market: $2.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
by Zacks Equity Research
AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.
AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints
by Zacks Equity Research
AzurRx (AZRX) is developing lead pipeline candidate as monotherapy and in combination regimen as potential treatment for exocrine pancreatic insufficiency in patients with cystic fibrosis.
New Strong Sell Stocks for August 5th
by Zacks Equity Research
AZRX, GHL, HEES, LGND, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2021.
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is likely to provide update related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports first-quarter 2021 results.
AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study
by Zacks Equity Research
AzurRX (AZRX) is developing its pipeline candidate, MS1819, as monotherapy as well in combination with standard of care for treating exocrine pancreatic insufficiency in patients with cystic fibrosis.
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis
by Zacks Equity Research
Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.
Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint
by Zacks Equity Research
Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.